Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

19.19 +0.17 (+0.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 845,400
Open 19.20
Bid (Size) 19.00 (1)
Ask (Size) 19.20 (4)
Prev. Close 19.02
Today's Range 18.88 - 19.61
52wk Range 18.21 - 40.59
Shares Outstanding 62,027,061
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Med Tech Stocks to Buy Now
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024
SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-45.37%
-45.37%
1 Month
-9.44%
-9.44%
3 Month
-19.10%
-19.10%
6 Month
-27.99%
-27.99%
1 Year
-49.57%
-49.57%

More News

Read More
Schrödinger Reports Strong Second Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Via Talk Markets
3 Small-Cap Stocks to Buy at a 52-Week Low
Via InvestorPlace
What Analysts Are Saying About Schrodinger Stock
Via Benzinga
Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
From Schrödinger
Via Business Wire
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Via Talk Markets
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
Simulations Plus Stock Drops 15% Despite EPS Beat
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Top-Rated Gene Editing Stocks Actually Making Money
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
Via Talk Markets
The 7 AI Categories Were Down 4%, On Average, This Week; Up 1% In May
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger to Present at Jefferies Global Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's the Difference Between Biotech Stocks and TechBio Stocks?
Via The Motley Fool
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
The 7 AI Categories Declined, On Average, The First Week Of May
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.